title: Personalized therapy for acute myeloid leukemia.
abstract: Patient-specific ex vivo drug sensitivity and resistance screening can identify rational drug candidates for the testing of personalized targeted therapy. An iterative approach of genomic and drug susceptibility characterization at sequential time points during clinical trials of targeted therapy in acute myeloid leukemia may be useful both for characterizing mechanisms of resistance and clonal evolution and also for identification of novel therapeutic targets and drug combinations.
authors: 1Myeloid Malignancies Section, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, and 2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
authors: Christopher S
authors: CS
authors: Hourigan
authors: Judith E
authors: JE
authors: Karp
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D057285:Precision Medicine / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents